Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
- Rimini M.
- Rimassa L.
- Ueshima K.
- Burgio V.
- Shigeo S.
- Tada T.
- Suda G.
- Yoo C.
- Cheon J.
- Pinato D. J.
- Lonardi S.
- Scartozzi M.
- Iavarone M.
- Di Costanzo G. G.
- Marra F.
- Solda C.
- Tamburini E.
- Piscaglia F.
- Masi G.
- Cabibbo G.
- Foschi F. G.
- Silletta M.
- Pressiani T.
- Nishida N.
- Iwamoto H.
- Sakamoto N.
- Ryoo B. -Y.
- Chon H. J.
- Claudia F.
- Niizeki T.
- Sho T.
- Kang B.
- D'Alessio A.
- Kumada T.
- Hiraoka A.
- Hirooka M.
- Kariyama K.
- Tani J.
- Atsukawa M.
- Takaguchi K.
- Itobayashi E.
- Fukunishi S.
- Tsuji K.
- Ishikawa T.
- Tajiri K.
- Ochi H.
- Yasuda S.
- Toyoda H.
- Ogawa C.
- Nishimur T.
- Hatanaka T.
- Kakizaki S.
- Shimada N.
- Kawata K.
- Tanaka T.
- Ohama H.
- Nouso K.
- Morishita A.
- Tsutsui A.
- Nagano T.
- Itokawa N.
- Okubo T.
- Arai T.
- Imai M.
- Naganuma A.
- Koizumi Y.
- Nakamura S.
- Joko K.
- Iijima H.
- Hiasa Y.
- Pedica F.
- De Cobelli F.
- Ratti F.
- Alrighetti L.
- Kudo M.
- Cascinu S.
- Casadei-Gardini A.
DOIAbstract
Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials and methods: We carried out a retrospective analysis of prospectively collected data from consecutive patients with non-viral advanced HCC, treated with atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers in 4 countries (Italy, Japan, Republic of Korea, and UK). The primary endpoint was overall survival (OS) with atezolizumab plus bevacizumab versus lenvatinib. Secondary endpoints were progression-free survival (PFS) with atezolizumab plus bevacizumab versus lenvatinib, and OS and PFS with atezolizumab plus bevacizumab versus sorafenib. For the primary and secondary endpoints, we c...
Add to ORKG